Most cited papers in HER2/EGFR in Cancer Research

HER2/EGFR in Cancer Research

What are the most cited papers in HER2/EGFR in Cancer Research?

The most cited paper in HER2/EGFR in Cancer Research is "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene" (Dennis J. Slamon, Gary M. Clark, Steven Wong et al., 1987), with 11,844 citations. Next come "Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2" (11,628) and "Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib" (11,595).

Published TypeAccessAuthorsCitations

Showing 50 of 97 papers. Every paper with more than 1,671 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science	9 Jan 1987	11,844
2	Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian R Leyland-Jones, Steven Shak et al. · New England Journal of Medicine Open access	15 Mar 2001	11,628
3	Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas James Lynch, Daphne W. Bell, Raffaella Sordella et al. · New England Journal of Medicine	19 May 2004	11,595
4	EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy J. Guillermo Paez, Pasi Antero Janne, Jeffrey C. Lee et al. · Science	3 May 2004	9,471
5	Cell Signaling by Receptor Tyrosine Kinases Mark A. Lemmon, Joseph Schlessinger · Cell Open access	Jun 2010	8,012
6	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al. · The Lancet Open access	Aug 2010	7,405
7	Untangling the ErbB signalling network Yosef Yarden, Mark X. Sliwkowski · Nature Reviews Molecular Cell Biology Review	Feb 2001	7,048
8	Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer Dennis J. Slamon, William J. Godolphin, Lovell Allan Jones et al. · Science	12 May 1989	6,879
9	pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up C.W. Elston, Ian Ogilvie Ellis · Histopathology	Nov 1991	6,254
10	Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies Brian David Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation Open access	10 Jun 2011	5,662
11	Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR Makoto Maemondo et al. · New England Journal of Medicine	23 Jun 2010	5,607
12	Signal transduction by receptors with tyrosine kinase activity Axel Ullrich, Joseph Schlessinger · Cell	Apr 1990	5,534
13	Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer Edward H. Romond et al. · New England Journal of Medicine Open access	20 Oct 2005	5,398
14	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Martine J Piccart et al. · New England Journal of Medicine Open access	20 Oct 2005	5,138
15	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer Antonio C. Wolff et al. · Journal of Clinical Oncology Open access	12 Dec 2006	4,487
16	Trastuzumab-Induced Hepatotoxicity: A Case Report Darko Vucicevic, Elizabeth J. Carey, Nina J. Karlin · Breast Care Open access	2013	4,419
17	EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib William J. Pao, Vincent A. Miller, Maureen Frances Zakowski et al. · Proceedings of the National Academy of Sciences Open access	25 Aug 2004	4,369
18	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray Christine P. Hans · Blood Open access	22 Sep 2003	4,323
19	American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer M. Elizabeth H. Hammond et al. · Journal of Clinical Oncology Open access	19 Apr 2010	4,301
20	Triple-Negative Breast Cancer William David Foulkes, Ian E. Smith, Jorge Sergio Reis-Filho · New England Journal of Medicine	10 Nov 2010	4,277
21	Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology	7 Oct 2013	4,103
22	EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib Susumu S. Kobayashi, Titus J. Boggon, Tajhal Dayaram et al. · New England Journal of Medicine Open access	23 Feb 2005	3,981
23	X-Tile Robert L. Camp, Marisa P Dolled-Filhart, David L. Rimm · Clinical Cancer Research	Nov 2004	3,979
24	Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Aron Goldhirsch, W. C. Wood, Alan Stuart Coates et al. · Annals of Oncology Open access	28 Jun 2011	3,932
25	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre et al. · New England Journal of Medicine Open access	Apr 2009	3,899
26	Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group Malcolm J. Moore, David B Goldstein, John Turner Hamm et al. · Journal of Clinical Oncology	24 Apr 2007	3,888
27	Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Sunil Verma, David W. Miles, Luca Gianni et al. · New England Journal of Medicine Open access	Oct 2012	3,859
28	Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 Aron Goldhirsch et al. · Annals of Oncology Open access	6 Aug 2013	3,776
29	Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Charles E. Geyer, John Forster, Deborah L. Lindquist et al. · New England Journal of Medicine Open access	27 Dec 2006	3,486
30	ERBB receptors and cancer: the complexity of targeted inhibitors Nancy E. Hynes, Heidi A. Lane · Nature reviews. Cancer Review	29 Apr 2005	3,349
31	A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes Richard M. Neve et al. · Cancer Cell Open access	Dec 2006	3,275
32	Epidermal growth factor receptor mutations in lung cancer Sreenath V. Sharma, Daphne W. Bell, Jeffrey E. Settleman et al. · Nature reviews. Cancer Review	23 Feb 2007	3,178
33	Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Rafael G. Amado, Michael Wolf, Marc Peeters et al. · Journal of Clinical Oncology Open access	3 Mar 2008	3,175
34	Breast cancer Nadia Harbeck, Frederique Madeleine Penault-Llorca, Javier Cortés et al. · Nature Reviews Disease Primers ReviewOpen access	23 Sep 2019	3,056
35	Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Charles L. Vogel · Journal of Clinical Oncology	Feb 2002	2,953
36	Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer Masahiro Fukuoka, Seiji Yano, Giuseppe Giaccone et al. · Journal of Clinical Oncology	20 May 2003	2,899
37	Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Stefan Paul Aebi, T. Davidson, Günther Gruber et al. · Annals of Oncology Open access	May 2010	2,861
38	Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial Louis Fehrenbacher, Alexander I. Spira, Marcus D. Ballinger et al. · The Lancet	9 Mar 2016	2,823
39	Drug penetration in solid tumours Andrew Ivor Minchinton, Ian F. Tannock · Nature reviews. Cancer Review	24 Jul 2006	2,815
40	Adjuvant Trastuzumab in HER2-Positive Breast Cancer Dennis J. Slamon et al. · New England Journal of Medicine Open access	5 Oct 2011	2,803
41	Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets Raphael Clynes, Terri L. Towers, Leonard G. Presta et al. · Nature Medicine	Apr 2000	2,775
42	Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer Shanu Modi et al. · New England Journal of Medicine Open access	5 Jun 2022	2,702
43	Epidermal growth factor-related peptides and their receptors in human malignancies David S. Salomon, Ralf Brandt, Fortunato Ciardiello et al. · Critical Reviews in Oncology/Hematology	Jul 1995	2,699
44	Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer Gϋnter von Minckwitz et al. · New England Journal of Medicine Open access	5 Dec 2018	2,689
45	Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma Torsten O. Nielsen, Forrest D. Hsu, Kristin C. Jensen et al. · Clinical Cancer Research Open access	15 Aug 2004	2,681
46	Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Fabrice André, Eva M. Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine Open access	15 May 2019	2,660
47	Triple-negative breast cancer molecular subtyping and treatment progress Li Yin, Jiang-Jie Duan, Xiu-Wu Bian et al. · Breast Cancer Research Open access	9 Jun 2020	2,604
48	Trastuzumab — Mechanism of Action and Use in Clinical Practice Clifford A. Hudis · New England Journal of Medicine	4 Jul 2007	2,603
49	Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2 Richard A. Morgan, James Chih-Hsin Yang, Mio Kitano et al. · Molecular Therapy Open access	23 Feb 2010	2,583
50	Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine Open access	7 Dec 2011	2,559

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for a field when OpenAlex files it under one of the field's topics; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.